Autor: John Lilja, Sam Salek, Aldo Alvarez, David Hamilton
Wydawca: Wiley
Dostępność: 3-6 tygodni
Cena: 871,50 zł
Przed złożeniem zamówienia prosimy o kontakt mailowy celem potwierdzenia ceny.
ISBN13: |
9780470725665 |
ISBN10: |
0470725664 |
Autor: |
John Lilja, Sam Salek, Aldo Alvarez, David Hamilton |
Oprawa: |
Hardback |
Rok Wydania: |
2008-04-21 |
Ilość stron: |
356 |
Wymiary: |
253x175 |
Tematy: |
MJ |
∗ Offers a social view of the activities leading to the timely patient access to medicines including: drug research, drug production, drug distribution, drug prescribing, drug information and drug control
∗ Provides theoretical models to enable pharmacists to understand the organization of drug systems in their particular global territory
∗ Written specifically with the needs of pharmacy students taking Master′s degrees in mind
Spis treści:
Preface.
1. Introduction.
1.1 Economic development.
1.2 Systems analysis.
Contextual Factors Which Influence a National Pharmaceutical System.
1.3 The actors in the pharmaceutical systems.
Health care professional groups.
Drug producers.
Drug control.
Patients and their organizations.
1.4 Evaluations.
Deciding about the aim of the evaluation.
The identification of the system and its goals.
The identification of the evaluation dimensions and the decision on how to measure these dimensions.
1.5 The collection of data.
1.6 The summary of the results and the formulation of conclusions.
1.7 Social constructionism and social representation theory.
1.8 The actor–spectator paradox.
1.9 The decision–making processes in the drug system.
1.10 How attitudes and beliefs change – the balance model.
1.11 Summary of the chapter.
References.
2. A historical perspective of drug research and diffusion.
2.1 The period of folk medicine.
2.2 The merchant period (1500 AD to the end of the eighteenth century).
2.3 The chemical period (the nineteenth century).
2.4 The animal testing period (from 1900 to the end of the 1930s).
2.5 The drug innovation period (from 1940 to 1964).
2.6 The post–Thalidomide period (1965 to present).
2.7 Future perspectives.
2.8 Summary of the chapter.
References.
3. National drug policies.
3.1 Efficient organization of drug support.<
br>3.2 Efficient organization of drug research.
3.3 Efficient organization of drug production.
3.4 Efficient organization of drug distribution.
3.5 An efficient system for drug consumption.
3.6 An efficient system of drug information.
3.7 Choice of drugs with high therapeutic powers.
3.8 Choice of drugs with few side effects.
3.9 Low drug costs.
3.10 How to develop and implement a national policy.
3.11 Summary of the chapter.
References.
4. Planning the drug support.
4.1 Patent and exclusivity policies.
4.2 Trade name policy vs. generic name policy.
4.3 Generic and therapeutic substitution.
4.4 Generic prescribing.
4.5 Drug registration.
4.6 Drug reimbursement policies/national health insurance systems.
4.7 The public and private drug sectors of developing countries.
4.8 The primary health care policy.
4.9 The essential drugs policy.
4.10 Summary of the chapter.
References.
5. Drug research.
5.1 Drug company strategies.
Drug companies focusing on research to find new chemical substances intended for the international market .
Drug companies concentrating on efficient drug chemical production (bulk production).
Companies concentrating on the marketing of non–patented ready–made drugs (generic production).
Drug companies concentrating on the marketing of drugs for self–medication.
Drug companies concentrating on the sales of herbal medicines.
5.2 Factors which determine the resources a drug company spends on R&D.
5.3 The selection of research areas by a drug company.
5.4 The research process.
5.5 The project decision.
5.6 The research administration after a project has been accepted .
5.7 Research productivity.
5.8 Ethical concerns in drug research.
5.9 Summary of the chapter.
References.
6. Drug production.
6.1 Background.
6.2 Variations between countries.
6.3 The decision regarding which drug(s)
to produce .
Production considerations.
Marketing considerations.
6.4 The organization of production lines.
6.5 Production of drug raw materials.
6.6 Drug quality.
6.7 The principles of technical assistance support.
6.8 The decision where to locate the plant.
6.9 The determination of production quantities.
6.10 Export decisions.
6.11 Summary of the chapter.
References.
7. Drug prices, cost controls and profits in the drug industry.
7.1 The price setting of raw materials.
7.2 The price setting of ready–made drugs.
7.3 The price setting of patented drugs.
7.4 The price setting of non–patented drugs (generic drugs).
7.5 Price Competition.
7.6 Cost controls.
Cost control agencies which do not negotiate on drug prices.
Agencies which negotiate with drug companies about drug prices and accept ‘reasonable’ quotations.
Agencies which negotiate about drug prices and only accept the cheapest (or a number of the cheapest) drug(s) fulfilling a specific medical need.
7.7 The prices a patient has to pay in the public sector in countries which have a public distribution system.
7.8 Drug prices at private pharmacies in developing countries.
7.9 Drug prices at private pharmacies in developing countries.
7.10 Summary of the chapter.
References.
8. Drug wholesaling and procurement.
8.1 Importation.
8.2 Different types of wholesale systems.
8.3 How to evaluate a wholesaling system.
8.4 Procurement.
8.5 Summary of the chapter.
References.
9. Drug retail distribution.
9.1Pharmaceutical care.
9.2 The degree of formal government control of outpatient pharmacies.
State owned systems.
Private systems with government control of drug prices and of the locations of pharmacies .
Private systems with state control of drug prices without location control.
Private systems without state control of drug prices and of the locations of ne
w pharmacies.
9.3 Drug distribution aims.
Short travel times to the pharmacy service.
A satisfactory range of drug preparations.
Convenient opening hours.
Safety.
Short waiting times for customers.
Drug information and customer–pharmacy staff interactions.
Suitable working conditions.
Ethical considerations.
Cooperation with other sectors of the health care system.
Low drug prices in the pharmacy.
An efficient organization.
9.4 Summary of the chapter.
References.
10. Drug consumption.
10.1 A historical perspective.
10.2 Measurement of drug consumption.
Sales value in monetary terms.
The weight of the drugs consumed.
Number of packages sold.
Number of prescriptions.
Number of dosages (or the number of tablets, litres of infusion solutions etc.).
Defined daily dose (DDD).
Prescribed daily dosage (PDD).
The percentage of the population using a drug.
10.3 Factors which determine the volume of a drug consumed in a country.
10.4 Factors found to be related to the volume of drug consumption.
Time.
The level of industrialization and income.
Cultural and organizational factors.
10.5 Factors which influence drug consumption at the individual level.
Skewed distribution.
Morbidity factors.
Age.
Sex.
Civil status.
Income and level of education.
Role of Media.
Other factors.
10.6 Qualitative studies of drug consumption.
10.7 Summary of the chapter.
References.
11. Marketing of drugs.
11.1 Historical background.
The transfer of production of raw drug materials from pharmacies to the drug industry (in Europe from the mid–nineteenth century to about the 1880s).
The selling of quasi–drug products outside the pharmacy system (in Europe from about 1880 to 1920).
The transfer of ready–made drug production from pharmacies to the drug industry (in Europe from about 1920 to 1950).
The introduction of new marke
Książek w koszyku: 0 szt.
Wartość zakupów: 0,00 zł
Gambit
Centrum Oprogramowania
i Szkoleń Sp. z o.o.
Al. Pokoju 29b/22-24
31-564 Kraków
Siedziba Księgarni
ul. Kordylewskiego 1
31-542 Kraków
+48 12 410 5991
+48 12 410 5987
+48 12 410 5989
Administratorem danych osobowych jest firma Gambit COiS Sp. z o.o. Na podany adres będzie wysyłany wyłącznie biuletyn informacyjny.
© Copyright 2012: GAMBIT COiS Sp. z o.o. Wszelkie prawa zastrzeżone.
Projekt i wykonanie: Alchemia Studio Reklamy